
A28 Therapeutics and GATC Health announce comprehensive AI analysis for AT-101 cancer drug candidate
A28 Therapeutics, a clinical-stage biopharmaceutical company, has recently announced the completion of a comprehensive activity analysis for its AT-101 cancer drug candidate. This announcement was made during the J.P. Morgan








